, /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: ) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that Dr. will be attending and presenting at the Allogeneic Cell Therapies Summit 6th Annual Meeting from in Dr.
, Chief Scientific and Medical Officer for Coeptis Therapeutics will be delivering two seminars regarding allogeneic products' starting materials. Panel Discussion: What Criteria Make the Ideal Starting Material for Allogeneic Products? Manufacturing Track Day One PM Overcoming Hurdles in Allogeneic Cell Therapy Development Using Pooled Donor Cord Blood CD34+ Cells as the Starting Material Conference Day One Dr. , Chief Scientific and Medical Officer for Coeptis Therapeutics commented, "Each year the Summit brings together leaders within the scientific community to discuss the future of allogeneic cell therapies.
This is a great platform to educate our peers on the progress we are making at Coeptis. With the integration of this cell generation platform with universal SNAP-CAR technology, we have the opportunity to reshape the current cancer treatment market." Coeptis Therapeutics Holdings, Inc.
, together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious d.